The reference with the strongest citation burst documented the efficacy of T-DM1 in the treatment of residual invasive HER2-positive breast cancer (Von Minckwitz et al., 2019), while in the clinical field, Rosenberg et al. (2019) reported the efficacy and safety data of enfortumab vedotin, an ADC drug that targets nectin-4, in the treatment of previously chemotherapy and immunotherapy treated urothelial carcinoma. The gene discussed is ERBB2; the disease is breast carcinoma.